Piccaluga Pier Paolo, Gazzola Anna, Mannu Claudia, Agostinelli Claudio, Bacci Francesco, Sabattini Elena, Sagramoso Carlo, Piva Roberto, Roncolato Fernando, Inghirami Giorgio, Pileri Stefano A
Hematopathology Section, Department of Hematology and Oncological Sciences "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy.
Adv Hematol. 2010;2010:345053. doi: 10.1155/2010/345053. Epub 2011 Feb 6.
The authors revise the concept of anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classification of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. The main histological findings are illustrated with special reference to the cytological spectrum that is indeed characteristic of the tumor. The phenotype is reported in detail: the expression of the ALK protein as well as the chromosomal abnormalities is discussed with their potential pathogenetic implications. The clinical features of ALCL are presented by underlining the difference in terms of response to therapy and survival between the ALK-positive and ALK-negative forms. Finally, the biological rationale for potential innovative targeted therapies is presented.
作者根据最近更新的世界卫生组织造血与淋巴组织肿瘤分类,从生物学和临床角度对间变性大细胞淋巴瘤(ALCL)的概念进行了修订。文中特别参照了该肿瘤特有的细胞学谱系,阐述了主要组织学发现。详细报告了其表型:讨论了ALK蛋白的表达以及染色体异常及其潜在的致病意义。通过强调ALK阳性和ALK阴性形式在治疗反应和生存方面的差异,介绍了ALCL的临床特征。最后,阐述了潜在创新靶向治疗的生物学原理。